A Study of LY3561774 in Participants With Mixed Dyslipidemia

Inclusion criteria

• Have fasting triglycerides (TGs) within the range of 150 (1.69 millimole/liter (mmoL) to 499 milligram/deciliter (mg/dL) 2.26 to 5.64 millimole/liter (mmol/L) at screening.
• Have fasting LDL-C ≥70 mg/dL (1.81 mmol/L) at screening.
• Have non-HDL-C ≥ 130 mg/dL (3.36 mmol/L) at screening.
• Must be on a stable moderate or high-intensity dose of a statin for at least 2 months before screening and remain on the same medication and dose for the duration of the study.
• Have a body mass index within the range of 18.5 to 40.0 kilogram/square meter (kg/m²), inclusive

Exclusion criteria

• Have in the 6 months prior to screening, uncontrolled Type 1 or Type 2 diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization, or have an hemoglobin A1c (HbA1c) ≥8% at screening.
• Have a history of nephrotic syndrome.
• Have a history of acute or chronic pancreatitis.
• Have had within the past 3 months prior to screening

• Myocardial infarction
• Unstable angina
• Coronary artery bypass graft
• Percutaneous coronary intervention - diagnostic angiograms are permitted
• Peripheral artery disease
• Transient ischemic attack, or
• Cerebrovascular accident
• Have New York Heart Association Class III or IV heart failure or last known left ventricular ejection fraction <30%.
• Have undergone LDL apheresis within 12 months prior to screening.
• Have clinically relevant anemia, as defined by the investigator.
• Have, within 1 year prior to screening or plan on having during the study, surgical treatment for obesity.
• Have within 3 years prior to screening a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse.
• Have uncontrolled hypertension.
• Have used or are taking products for the purpose of lowering lipid levels (except for statins, PCSK9 inhibitors, bempedoic acid, and ezetimibe). This includes lipid-regulating medication, over-the-counter products, or herbal therapies.